Pier F Ferrucci

Summary

Affiliation: European Institute of Oncology
Country: Italy

Publications

  1. ncbi request reprint Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer
    Pier Francesco Ferrucci
    Divisions of Hemato oncology and Biostatistics and Epidemiology, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 10:6039-46. 2004
  2. ncbi request reprint Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment
    P F Ferrucci
    Melanoma and Muscle Cutaneous Sarcomas Division, IEO European Institute of Oncology, Milan, Italy
    Curr Top Med Chem 12:11-31. 2012
  3. ncbi request reprint Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?
    Pier Francesco Ferrucci
    Department of Haematoncology, European Institute of Oncology IEO, Milan, Italy
    Br J Haematol 136:521-38. 2007
  4. ncbi request reprint A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer
    P F Ferrucci
    Division of Hemato Oncology, European Institute of Oncology, I 20141 Milan, Italy
    Int J Oncol 30:955-62. 2007
  5. ncbi request reprint High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas
    Pier F Ferrucci
    Melanoma and Sarcoma Division, European Institute of Oncology, Milan, Italy
    Br J Haematol 139:590-9. 2007
  6. doi request reprint Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach
    Alessandro Testori
    Melanoma and Muscle Cutaneous Sarcoma Division, European Institute of Oncology, Milan, Italy
    Dermatol Ther 23:651-61. 2010
  7. doi request reprint HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future
    Giulio Tosti
    Division of Melanoma and Muscle Cutaneous Sarcomas, IEO, European Institute of Oncology, Milan, Italy
    Expert Rev Vaccines 8:1513-26. 2009
  8. doi request reprint Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. (IELSG 4). [corrected]
    Giovanni Martinelli
    Division of Haematoncology, European Institute of Oncology, Milan, Italy
    Leuk Lymphoma 50:925-31. 2009
  9. ncbi request reprint Oncophage: step to the future for vaccine therapy in melanoma
    Alessandra di Pietro
    Division of Melanoma and Musculo Cutaneous Sarcomas, IEO European Institute of Oncology, 435, Via Giuseppe Ripamonti, 20141 Milan, Italy
    Expert Opin Biol Ther 8:1973-84. 2008
  10. ncbi request reprint High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment
    Marta Cremonesi
    Division of Medical Physics, European Institute of Oncology, Milan, Italy
    J Nucl Med 48:1871-9. 2007

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer
    Pier Francesco Ferrucci
    Divisions of Hemato oncology and Biostatistics and Epidemiology, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 10:6039-46. 2004
    ..The population on which the study was conducted was drawn from stage III breast cancer patients undergoing high-dose chemotherapy and autologous transplantation with PBPCCs...
  2. ncbi request reprint Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment
    P F Ferrucci
    Melanoma and Muscle Cutaneous Sarcomas Division, IEO European Institute of Oncology, Milan, Italy
    Curr Top Med Chem 12:11-31. 2012
    ....
  3. ncbi request reprint Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?
    Pier Francesco Ferrucci
    Department of Haematoncology, European Institute of Oncology IEO, Milan, Italy
    Br J Haematol 136:521-38. 2007
    ....
  4. ncbi request reprint A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer
    P F Ferrucci
    Division of Hemato Oncology, European Institute of Oncology, I 20141 Milan, Italy
    Int J Oncol 30:955-62. 2007
    ..06) respectively. These data confirm the activity of MAM as a negative prognostic factor and show for the first time that MAS could work as a tumor suppressor gene even in a clinical setting, since it protects from recurrence...
  5. ncbi request reprint High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas
    Pier F Ferrucci
    Melanoma and Sarcoma Division, European Institute of Oncology, Milan, Italy
    Br J Haematol 139:590-9. 2007
    ..Maximum tolerated dose was not clearly defined according to dosimetry and clinical toxicities, and further studies are needed to confirm the toxicity profile and evaluate efficacy...
  6. doi request reprint Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach
    Alessandro Testori
    Melanoma and Muscle Cutaneous Sarcoma Division, European Institute of Oncology, Milan, Italy
    Dermatol Ther 23:651-61. 2010
    ..ECT can be proposed as loco-regional therapy for disseminated cutaneous and subcutaneous tumor lesions as alternative treatment modality to conventional therapies or as palliative care, in order to improve patients' quality of life...
  7. doi request reprint HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future
    Giulio Tosti
    Division of Melanoma and Muscle Cutaneous Sarcomas, IEO, European Institute of Oncology, Milan, Italy
    Expert Rev Vaccines 8:1513-26. 2009
    ..Heat-shock protein-based vaccines can be considered as a novel therapeutic approach with a promising role in cancer management...
  8. doi request reprint Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. (IELSG 4). [corrected]
    Giovanni Martinelli
    Division of Haematoncology, European Institute of Oncology, Milan, Italy
    Leuk Lymphoma 50:925-31. 2009
    ..Our results confirm that CT could be considered as first line therapy for newly diagnosed gastric DLBC lymphoma; IF RT delivered in those patients achieving CR after induction CT is able to prevent local relapse...
  9. ncbi request reprint Oncophage: step to the future for vaccine therapy in melanoma
    Alessandra di Pietro
    Division of Melanoma and Musculo Cutaneous Sarcomas, IEO European Institute of Oncology, 435, Via Giuseppe Ripamonti, 20141 Milan, Italy
    Expert Opin Biol Ther 8:1973-84. 2008
    ..Thus, HSP-based vaccines are a novel therapeutic approach with a promising role in cancer management...
  10. ncbi request reprint High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment
    Marta Cremonesi
    Division of Medical Physics, European Institute of Oncology, Milan, Italy
    J Nucl Med 48:1871-9. 2007
    ..The second goal was to verify the safety of the prescribed activity and the best timing of stem cell reinfusion...